This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).
18 years or older
Provides voluntary written informed consent
Relapsed or refractory large B-cell lymphoma (LBCL) or chronic lymphocytic leukemia (CLL)
Measurable disease according to Lugano 2014 criteria (LBCL) or iwCLL 2018 (CLL).
Women who are pregnant or breastfeeding
Current isolated central nervous system (CNS) involvement
Prior allogeneic bone marrow transplant, gene therapy, or adoptive cell transfer (exceptions include tumor-infiltrating lymphocytes and CAR T cells)
History of or active human immunodeficiency virus (HIV)
Sequential
UB-VV111
GeneticUB-VV111 is a gene therapy that generates CD19 CAR T cells in the body.
rapamycin
DrugRapamycin is an FDA-approved drug.
Percentage of participants with common adverse events (AEs)
Percentage of participants with commonly reported AEs overall and by severity
Overall response rate (ORR)
Percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR)
Click on the lead sponsor to view all of their trials.
